Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
An Open-label, Multicenter Study to Evaluate Pharmacokinetics, Safety and Tolerability up to 6 Years of Intravenous Secukinumab Infusions in Pediatric Participants With Juvenile Psoriatic Arthritis
Sponsor: Novartis Pharmaceuticals
Listed as NCT06751238, this PHASE1 trial focuses on Juvenile Psoriatic Arthritis and remains actively recruiting participants. Sponsored by Novartis Pharmaceuticals, it has been updated 6 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE1
-
Jan 2026 — Mar 2026 [monthly]
Recruiting PHASE1
-
Nov 2025 — Jan 2026 [monthly]
Recruiting PHASE1
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE1
-
May 2025 — Oct 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Jan 2025 — May 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .